

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 December 2022 (22.12.2022)




(10) International Publication Number
WO 2022/266318 A2

- (51) **International Patent Classification:**
A61K 31/522 (2006.01) *A61P 31/04* (2006.01)
- (21) **International Application Number:**
PCT/US2022/033786
- (22) **International Filing Date:**
16 June 2022 (16.06.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/211,320 16 June 2021 (16.06.2021) US
63/236,972 25 August 2021 (25.08.2021) US
63/263,556 04 November 2021 (04.11.2021) US
63/264,052 15 November 2021 (15.11.2021) US
- (71) **Applicant:** ACURX PHARMACEUTICALS LLC
[US/US]; 22 Camelot Court, White Plains, New York 10603 (US).
- (72) **Inventor:** GAREY, Kevin; 311 W. 24th Street, Houston, Texas 77018 (US).
- (74) **Agent:** YELLIN, Deborah; Crowell & Moring LLP, 1001 Pennsylvania Ave NW-Floor 10, United States of America, Washington, District of Columbia 20004 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) **Title:** USE OF IBEZAPOLSTAT TO PROMOTE MICROBIOME HEALTH

Fig. 1

Alpha diversity changes during the course of therapy



(57) **Abstract:** The invention relates to methods of using ibezapolstat to increase the health of the gut microbiome. The invention provides methods of simultaneously treating *C. difficile* infections while at the same time reducing the likelihood of or preventing the recurrence of *C. difficile* infection. The invention also provides methods of increasing the health of the gut microbiome by increasing the number of Actinobacteria and/or Firmicutes in the gut.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*